Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Women's Health and Genetics/Laboratory Corporation of America, |
RCV001328416 | SCV001519534 | uncertain significance | not specified | 2021-03-09 | criteria provided, single submitter | clinical testing | Variant summary: FANCL c.1051_1052dupAG (p.Ser351ArgfsX19) results in a premature termination codon, not anticipated to result in nonsense mediated decay, but predicted to cause a truncation of the encoded protein, disrupting the last 25 amino acids of the FANCL protein. This truncation is expected to remove two conserved, metal ion binding Cys residues that are part of the RING-type Zinc finger domain of the FANCL protein (amino acids 307 - 365; UniProt). This C-terminal domain is necessary for monoubiquitination of FANCD2 (see e.g. PMID 32048394). The variant allele was found at a frequency of 4e-06 in 250738 control chromosomes (gnomAD). To our knowledge, no occurrence of c.1051_1052dupAG in individuals affected with Fanconi Anemia and no experimental evidence demonstrating its impact on protein function have been reported. However, a downstream truncation variant (c.1096_1099dupATTA (p.Thr367AsnfsX13)), has been reported in the literature in a compound heterozygous patient with milder features of Fanconi anemia (FA), and functional studies suggested that this variant results in a partial loss of FANCL activity, indicating a hypomorphic effect for the variant; this study also demonstrated that the variant found on the opposite allele (in trans) in this patient was a functionally null mutation (PMID 19405097). On the other hand, the variant, c.1095_1098dupAATT, was also reported t in several homozygous control individuals in the gnomAD database, suggesting that this variant might not be sufficient to cause FA phenotype in homozygous state. An overlapping truncation variant (c.1048_1051delCAGA (p.Gln350ValfsX18)), was also described in the literature in a heterozygous patient with premature ovary insufficiency (POI), and authors of this study demonstrated that while the wildtype FANCL protein was predominantly localized in the nuclei, the variant FANCL protein was retained in the cytoplasm, in addition, this variant resulted in loss of ubiquitinligase activity and decreased DNA damage repair capacity (PMID 32048394). Based on their findings, authors proposed haploinsufficiency as a potential causative mechanism for the (provisional) POI phenotype. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic. |
| Fulgent Genetics, |
RCV002504517 | SCV002814304 | uncertain significance | Fanconi anemia complementation group L | 2021-07-13 | criteria provided, single submitter | clinical testing |